Dolutegravir alone versus with tenofovir for HTLV-1
Treatments studied
Part of Blood & lymphatic, Brain & nervous system, Cancer, Immune system & allergy, Infections clinical trials.
This study tests whether adding tenofovir (an antiviral medication) to dolutegravir helps treat HTLV-1 infection better than dolutegravir alone. HTLV-1 is a virus that can cause serious health problems, and researchers want to find the most effective treatment combination.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have confirmed HTLV-1 infection (a blood test showing the virus)
- You have symptoms or health problems caused by HTLV-1
- You do not have HIV, hepatitis C, or hepatitis B infections
- You do not have active tuberculosis
- Your kidneys function well enough (not severely damaged)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two HIV medicines, doravirine and dolutegravir, to see which works better for people who have never taken HIV treatment before. If you qualify, you would be randomly assigned to one of the two medications.
This trial tests a two-drug HIV treatment for people who are new to HIV therapy and also have tuberculosis. It compares the two-drug combination to the standard three-drug regimen, with the goal of making treatment simpler while still being effective.
This trial tests better ways to manage HIV when the virus becomes resistant to dolutegravir (DTG), a key medicine. It is for people with high viral load despite being on DTG for at least six months.
This study collects information from people with HIV who are either starting HIV treatment for the first time or switching from a three-drug regimen to a two-drug regimen with dolutegravir and lamivudine. The goal is to build a database to learn how well this dual therapy works in real-world practice.
This trial studies whether taking dolutegravir plus lamivudine (a simpler two-drug regimen) can work as well as a standard three-drug HIV regimen for people who have reasons they can’t stay on the usual medicines. You may be offered free treatment if you meet the safety checks and can attend follow-up visits.
This study tests a two-drug HIV treatment combination (dolutegravir and lamivudine) for pregnant women who have never taken HIV medicine before. The goal is to see if this combination safely controls HIV during pregnancy and protects the baby.
Hear when a new HTLV-1 Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.